Biodesix Inc. receives mostly "Buy" ratings with a $3.06 price target after Q2 earnings report of $0.08 per share loss and $17.93 million revenue.
Biodesix, Inc., a U.S.-based diagnostic solutions provider, has garnered an average "Buy" rating from seven analysts, with a 12-month price target of $3.06. The stock opened at $1.74. Recent reports show a Q2 earnings loss of $0.08 per share, which exceeded expectations, alongside revenue of $17.93 million. The company specializes in blood-based lung cancer tests, and hedge funds have recently adjusted their investments in Biodesix.
September 19, 2024
3 Articles